Högger Petra
Institut für Pharmazie und Lebensmittelchemie Bayerische, Julius-Maximilians-Universität, Würzburg, Germany.
Curr Opin Pulm Med. 2003 Jan;9(1):1-8. doi: 10.1097/00063198-200301000-00001.
Inhaled glucocorticoids play an indispensable role in the therapy of asthma. Development of new compounds was initially directed to increase the potency of the individual corticosteroid; thereafter, pharmacokinetic characteristics were modified to reduce unwanted systemic effects. Target of the present development is to attain compounds with the most favorable risk-to-benefit ratios. Since then, there has been substantial discussion about how to rank and weigh the different glucocorticoids. This article provides an evaluation of the relevant clinical studies published between May 2001 and June 2002, identifying the main determinants of the therapeutic value of inhaled glucocorticoids.
吸入性糖皮质激素在哮喘治疗中发挥着不可或缺的作用。新化合物的研发最初旨在提高单个皮质类固醇的效力;此后,对药代动力学特性进行了改良,以减少不必要的全身效应。当前研发的目标是获得风险效益比最有利的化合物。从那时起,关于如何对不同的糖皮质激素进行排名和权衡,一直存在大量讨论。本文对2001年5月至2002年6月间发表的相关临床研究进行了评估,确定了吸入性糖皮质激素治疗价值的主要决定因素。